Afrin Firfiray

Afrihealth Optonet Association — Nigeria

Medicine · Health Sciences

5h-index56citations15works1.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(11), Biosimilars and Bioanalytical Methods(8), Nanoparticle-Based Drug Delivery(1), Cancer Immunotherapy and Biomarkers(1), Advancements in Semiconductor Devices and Circuit Design(1)

Publications15 total

Early use of talicabtagene autoleucel in r/r B-acute lymphoblastic leukemia is cost-effective: Improved efficacy, reduced toxicity and healthcare resource utilization support affordable access
Blood·2025Open Access
Tali-cel is a safe and effective therapy in patients with Relapsed/Refractory B-cell non-Hodgkin lymphoma that allows equitable access- a real-world experience from India.
Blood·2025Open Access
A multicentre Phase I clinical trial demonstrates manufacturing feasibility, safety and activity of novel humanized BCMA-directed CAR-T cell therapy.
Blood·2025
Development of equitable access model for nationwide implementation of affordable CAR-T cell therapy in India: a real-world experience.
Cytotherapy·2025· 1 cited
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study
The Lancet Haematology·2025· 8 cited
Talicabtagene Autoleucel (humanized CD19 CAR-T) As a Second Line Therapy in r/r B-Cell Lymphoma: Sub-Analysis from a Phase I/II Trial
Blood·2024· 2 citedOpen Access
Development of a Novel Humanized BCMA-Directed CAR for Multiple Myeloma: Robust Activity and Low Toxicity in Preclinical Studies
Blood·2024· 1 citedOpen Access
Real World Data of Novel Talicabtagene Autoleucel (humanized CD19 CAR-T) from India; Ensuring Equitable Access with Excellent Safety and Efficacy Profile
Blood·2024· 5 cited
An Analysis of Infectious Complications Post-Treatment With Actalycabtagene Autoleucel
Clinical Lymphoma Myeloma & Leukemia·2024
CT-643 An Analysis of Infectious Complications Post-Treatment With Actalycabtagene Autoleucel
Clinical Lymphoma Myeloma & Leukemia·2024· 1 cited
Excellent Safety Profile of a Low-Cost Novel Humanized CD19 CAR T-Cell Therapy, Actalycabtagene Autoleucel : Potential Impact on Access and Feasibility
Blood·2023· 2 citedOpen Access
High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial
Blood·2023· 12 cited
<i>E</i>valuating the <i>S</i>afety of HCAR19 (Now Actalycabtagene Autoleucel- Actaly-Cel™), a Novel <i>H</i>umanized CD19-Directed Chimeric Antigen Receptor T-Cells in Pediatric, Adolescents, and Young Adults with Relapsed/ Refractory B- Acute Lymphoblastic Leukemia (ESHA) - Report of Phase-1B
Blood·2023· 6 cited
Phase I Trial of Humanized CD19 CART-Cell Therapy Developed in India: Safe, Active and Feasible for Outpatient Therapy
Blood·2022· 5 cited
Making Anti-CD19 CAR-T Cell Therapy Accessible and Affordable: First-in-Human Phase I Clinical Trial Experience from India
Blood·2022· 13 cited

Frequent Co-authors

Atharva Karulkar(15), Rahul Purwar(15), Shreshtha Shah(14), Juber Pendhari(13), Smrithi Ravikumar(12), Manju Sengar(12), Hasmukh Jain(11), Devanshi Kalra(11), Nirali N. Shah(10), Lingaraj Nayak(10), Bhausaheb Bagal(10), Ankesh Kumar Jaiswal(8), Aalia Khan(7), Gaurav Narula(7), Alok Shetty(6), Sattva S. Neelapu(6), Anand Vaibhaw(6), Ashish Saroha(6), Sweety Asija(5), Preeti Desai(5)